Structured financial advisory for pharmaceutical and medical device businesses navigating R\&D investment, regulatory compliance, and manufacturing scale-up financing.
Industry Overview
The Pharmaceuticals and Medical Devices sector is among the most globally competitive manufacturing industries, with domestic businesses supplying APIs, generics, biologics, and medical devices to regulated markets across the US, Europe, and emerging economies. With PLI schemes for bulk drugs and medical devices, CDSCO-regulated manufacturing compliance, and growing investment in biosimilars and specialty generics, businesses across the value chain — from API manufacturers to finished dosage form exporters — are investing in capacity and quality systems that require substantial, well-structured capital commitment.
The financing challenges are significant: regulatory compliance with CDSCO, US FDA, WHO GMP, and EU GMP standards requires continuous capital investment in quality systems, documentation, and facility upgrades that do not translate directly into revenue growth but are non-negotiable for market access. R&D expenditure for new formulations and biosimilars is long-horizon and uncertain in timeline, and working capital requirements — driven by API inventory cycles, export receivables, and regulatory testing timelines — are consistently underestimated by lenders applying standard manufacturing credit norms to pharma businesses.
Arthasetu Fin Hub works with API manufacturers, formulation companies, CROs, medical device manufacturers, and pharma exporters to structure financing that reflects the regulatory intensity and capital requirements of operating in this sector. From R&D-linked term loans and export working capital to credit rating preparation and pre-IPO advisory for businesses approaching public markets, we help pharma businesses access structured capital from the right lenders and institutions.
Sector Challenges
Maintaining US FDA, WHO GMP, and EU GMP approvals requires continuous investment in quality systems, documentation infrastructure, and facility upgrades — expenditure that is mandatory for market access but does not show up as revenue-generating CapEx on a balance sheet. Lenders that do not understand this sector consistently undervalue compliance investment as an indicator of business quality and bankability.
API procurement lead times of 60 to 120 days, combined with regulatory testing, batch release, and export documentation processes, create working capital cycles that are significantly longer than standard manufacturing. Businesses simultaneously hold large raw material, WIP, and finished goods inventory — with working capital requirements that standard limits cannot accommodate at full production capacity.
Exporting to regulated markets in the US and Europe involves extended buyer credit terms, letter of credit management, and payment timelines that stretch 60 to 150 days from shipment. Without structured export bill discounting and pre-shipment credit facilities, pharma exporters are effectively financing international buyers at the cost of their own working capital position.
How We Help
We structure working capital and term loan facilities that account for API inventory cycles, regulatory testing timelines, and export receivable patterns — ensuring credit limits are adequate for full-capacity operations across the production cycle.
Explore ServiceWe help pharma exporters unlock working capital tied in international buyer receivables through structured export bill discounting facilities — allowing businesses to service more orders without waiting 90 to 150 days for payment.
Explore ServiceWe prepare financial documentation, regulatory compliance positioning, and sector-specific business case needed to secure a strong credit rating — improving lender confidence and reducing borrowing costs for larger facilities.
Explore ServiceFor pharma companies approaching public markets, we provide financial restructuring, regulatory compliance documentation, governance strengthening, and investor readiness advisory to position the business for a successful pre-IPO round or listing.
Explore ServiceWhy Arthasetu
We help lenders understand that US FDA, WHO GMP, and EU GMP compliance is a premium indicator of business quality and creditworthiness — not simply a cost centre — improving the credit assessment and terms your business receives.
Our credit structures account for API lead times, batch testing periods, and export documentation timelines — not standard 90-day cycles that leave pharma businesses systematically underfunded at full production.
We structure pre-shipment credit and export bill discounting solutions that allow pharma exporters to scale international order volumes without being constrained by buyer credit terms that tie up working capital for months.
Our advisory spans the full capital journey — from working capital and term loans for operational businesses through to pre-IPO and public market advisory for companies approaching the next stage of growth.
Get Started
Talk to Arthasetu's advisors about structured working capital, export credit facilities, and growth capital solutions designed for pharmaceutical and medical device businesses.
Manufacturing Sector